'''Vanoxerine''' ('''GBR-12909''') is a [[piperazine]] derivative which is a potent and selective [[dopamine reuptake inhibitor]] (DRI). GBR-12909 binds to the target site on the [[dopamine transporter]] (DAT) ~ 50 times more strongly than [[cocaine]],<ref>{{cite journal |last1=Izenwasser |first1=Sari |last2=Werling |first2=Linda L. |last3=Cox |first3=Brian M. |title=Comparison of the effects of cocaine and other inhibitors of dopamine uptake in rat striatum, nucleus accumbens, olfactory tubercle, and medial prefrontal cortex |journal=Brain Research |volume=520 |issue=1–2 |pages=303–9 |year=1990 |pmid=2145054 |doi=10.1016/0006-8993(90)91719-W }}</ref> but simultaneously inhibits the release of dopamine. This combined effect only slightly elevates [[dopamine]] levels, giving vanoxerine only mild stimulant effects.<ref>{{cite journal |last1=Singh |first1=Satendra |title=Chemistry, Design, and Structure−Activity Relationship of Cocaine Antagonists |journal=Chemical Reviews |volume=100 |issue=3 |pages=925–1024 |year=2000 |pmid=11749256 |doi=10.1021/cr9700538 }}</ref> Vanoxerine has also been observed to be a  potent blocker of the IKr (hERG) channel.<ref name="Cakulev2011">{{cite journal |last1=Cakulev |first1=Ivan |last2=Lacerda |first2=Antonio E. |last3=Khrestian |first3=Celeen M. |last4=Ryu |first4=Kyungmoo |last5=Brown |first5=Arthur M. |last6=Waldo |first6=Albert L. |title=Oral Vanoxerine Prevents Reinduction of Atrial Tachyarrhythmias: Preliminary Results |journal=Journal of Cardiovascular Electrophysiology |volume=22 |issue=11 |pages=1266–73 |year=2011 |pmid=21615815 |pmc=3172341 |doi=10.1111/j.1540-8167.2011.02098.x }}</ref> '''GBR-12909''' also binds with nanomolar affinity to the serotonin transporter.<ref>http://kidbdev.med.unc.edu/databases/pdsp.php?knowID=0&kiKey=&recDDRadio=recDDRadio&receptorDD=101&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testLigandDD=&testLigand=&referenceDD=&reference=&KiGreater=&KiLess=&doQuery=Submit+Query</ref>

 
Vanoxerine has been researched for use in treating [[cocaine dependence]] both as a substitute for cocaine and to block the rewarding effects. This strategy of using a competing [[agonist]] with a longer half-life has been successfully used to treat addiction to opiates such as [[heroin]] by substituting with [[methadone]]. It was hoped that vanoxerine would be of similar use in treating cocaine addiction.<ref>{{cite journal |last1=Vetulani |first1=Jerzy |title=Drug addiction. Part III. Pharmacotherapy of addiction |journal=Polish Journal of Pharmacology |volume=53 |issue=5 |pages=415–34 |year=2001 |pmid=11990060 |doi= |url=http://www.if-pan.krakow.pl/pjp/pdf/2001/5_415.pdf }}</ref><ref>{{cite journal |last1=Preti |first1=Antonio |title=New developments in the pharmacotherapy of cocaine abuse |journal=Addiction Biology |volume=12 |issue=2 |pages=133–51 |year=2007 |pmid=17508985 |doi=10.1111/j.1369-1600.2007.00061.x }}</ref>

 
Research also indicates that vanoxerine may have additional mechanisms of action including antagonist action at [[nicotinic acetylcholine receptor]]s,<ref>{{cite journal |last1=Szasz |first1=B.K. |last2=Vizi |first2=E.S. |last3=Kiss |first3=J.P. |title=Nicotinic acetylcholine receptor antagonistic property of the selective dopamine uptake inhibitor, GBR-12909 in rat hippocampal slices |journal=Neuroscience |volume=145 |issue=1 |pages=344–9 |year=2007 |pmid=17207584 |doi=10.1016/j.neuroscience.2006.11.032 }}</ref> and it has also been shown to reduce the consumption of alcohol in animal models of alcohol abuse.<ref>{{cite journal |last1=Kamdar |first1=N. K. |last2=Miller |first2=S. A. |last3=Syed |first3=Y. M. |last4=Bhayana |first4=R. |last5=Gupta |first5=T. |last6=Rhodes |first6=J. S. |title=Acute effects of Naltrexone and GBR 12909 on ethanol drinking-in-the-dark in C57BL/6J mice |journal=Psychopharmacology |volume=192 |issue=2 |pages=207–17 |year=2007 |pmid=17273875 |doi=10.1007/s00213-007-0711-5 }}</ref>

 
Vanoxerine has been through human trials up to Phase II,<ref>{{cite journal |last1=Søgaard |first1=U. |last2=Michalow |first2=J. |last3=Butler |first3=B. |last4=Laursen |first4=A. Lund |last5=Ingersen |first5=S. H. |last6=Skrumsager |first6=B. K. |last7=Rafaelsen |first7=O. J. |title=A Tolerance Study of Single and Multiple Dosing of the Selective Dopamine Uptake Inhibitor GBR 12909 in Healthy Subjects |journal=International Clinical Psychopharmacology |volume=5 |issue=4 |pages=237–51 |year=1990 |pmid=2150527 |doi=10.1097/00004850-199010000-00001 }}</ref><ref>{{cite journal |last1=Preti |first1=A |title=Vanoxerine National Institute on Drug Abuse |journal=Current Opinion in Investigational Drugs |volume=1 |issue=2 |pages=241–51 |year=2000 |pmid=11249581 }}</ref><ref>{{cite journal |last1=Gorelick |first1=David A |last2=Gardner |first2=Eliot L |last3=Xi |first3=Zheng-Xiong |title=Agents in Development for the Management of Cocaine Abuse |journal=Drugs |volume=64 |issue=14 |pages=1547–73 |year=2004 |pmid=15233592 |doi=10.2165/00003495-200464140-00004 }}</ref> but development was stopped due to observed [[QT interval#Correction for heart rate|QTc]] effects in the context of cocaine use.<ref>{{cite journal |last1=Herman |first1=Barbara H. |last2=Elkashef |first2=Ahmed |last3=Vocci |first3=Frank |title=Medications for the treatment of cocaine addiction: Emerging candidates |journal=Drug Discovery Today |volume=2 |issue=1 |year=2005 |pages=87–92 |doi=10.1016/j.ddstr.2005.05.014}}</ref>

 
In clinical human trials with increasing dosages, vanoxerine has shown to have a highly favourable therapeutic index, showing no side effects at concentrations much higher than the therapeutic dose.<ref name="Cakulev2011" />   In canines, the effective therapeutic dose was between 76&nbsp;ng/ml and 99&nbsp;ng/ml, however the drug reached plasma concentrations of 550&nbsp;ng/ml without harmful side effects, presenting a desirable therapeutic index.<ref name="Cakulev2011" />

 
One of the major benefits of vanoxerine is that it does not appear to cause the same harmful side effects as its most comparable contender, [[amiodarone]].<ref name="Lacerda2010" />
